RxDoctor Payments Data

Rebecca Smith, MD

Family Medicine · Simpsonville, SCNPI 1407890932

Payments from drug & device makers

$6,436in general payments, 2019–2025

Across 177 payments — averaging $36.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3K
  • Novo Nordisk$303
  • AbbVie$275
  • Novartis$265
  • GSK$260
  • Abbott$220
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$3,00047%
  • Food & beverage$3,40653%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,436 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$113,075
Medicare patients
234
Services billed
2,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide67$99,228
JardianceEmpagliflozin60$81,986
OzempicSemaglutide50$69,169
EliquisApixaban57$53,042
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$45,070
XareltoRivaroxaban15$17,403
TrintellixVortioxetine Hydrobromide12$10,464
Tresiba Flextouch U-200Insulin Degludec11$9,884
GemtesaVibegron11$9,218
JanuviaSitagliptin Phosphate14$7,687
Tresiba Flextouch U-100Insulin Degludec11$7,679
Colesevelam Hcl21$2,850
SynthroidLevothyroxine Sodium35$2,658
Bupropion XlBupropion Hcl96$2,482
Atorvastatin Calcium291$2,383

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$147$99,22867 claims
Boehringer IngelheimJardiance$205$81,98660 claims
Novo NordiskOzempic$303$69,16950 claims
PfizerEliquis$3,377$53,04257 claims
GSKTrelegy Ellipta$260$45,07045 claims
Johnson & JohnsonXarelto$55$17,40315 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$10,46412 claims
MerckJanuvia$42$7,68714 claims
AbbVieSynthroid$275$2,65835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Simpsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →